NASDAQ · CYPH
Cypherpunk Technologies Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CYPH: Nov 11, 2026
Cypherpunk Technologies Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.08.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · RTTNews · Quiver Quantitative- The Motley Fool · Oct 10, 3:41 PM EDT2 Cryptocurrencies Poised to Surge 100% in the Coming Years That Savvy Investors Are Already BuyingA handful of high-profile investors have been buying Zcash and Hyperliquid lately.
- The Motley Fool · Sep 21, 6:50 AM EDT2 Cryptocurrencies Worth Buying Over AI Stocks Right NowBuying AI or semiconductor stocks right now means anticipating that their rapid growth rates will continue or even accelerate.
- Fintel · Sep 15, 12:21 PM EDTCypherpunk Technologies Consensus Price Target Increased by 206.25% to $5.00The average one-year price target for Cypherpunk Technologies (NASDAQCM:CYPH) has been revised to $5.00 / share. This is an increase of 206.25% from the prior estimate of $1.63 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not
- RTTNews · Sep 4, 7:44 AM EDTCypherpunk Swings To Q2 Profit On Zcash Treasury Gains; Advances Phase 3 Sirexatamab Plans;Stock Up(RTTNews) – Cypherpunk Technologies Inc. (CYPH), a privacy technology company focused on its Zcash treasury strategy and privacy-focused investments, recently reported a second-quarter profit, primarily driven by an unrealized gain on the fair value of its ZEC holdings.
- RTTNews · Sep 3, 2:30 PM EDTBiotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains(RTTNews) – Today's top gainers in the biotech and healthcare space include BioXcel Therapeutics, following an asset sale agreement with Teva and Chapter 11 filing; bioAffinity Technologies, on strong CyPath Lung testing growth; Cypherpunk Technologies, amid continued Zcash treas
- The Motley Fool · Aug 14, 7:23 AM EDTLeap Therapeutics Slashes R&D SpendingNet loss per share (GAAP) was $(0.40) in Q2 2025, missing analyst estimates by $(0.11).
- RTTNews · Jun 23, 8:04 AM EDTLeap Therapeutics Initiates Process To Explore Strategic Options(RTTNews) – Leap Therapeutics (LPTX) said it has initiated a process to explore strategic alternatives, including leveraging cash balance and exploring potential sale or partnership opportunities for sirexatamab and FL-501. The company is taking additional steps to reduce spendin
- RTTNews · May 13, 7:02 AM EDTLeap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates(RTTNews) – Leap Therapeutics, Inc. (LPTX) (LPTX) reported Loss for first quarter that beat the Street estimates.
- Quiver Quantitative · Mar 26, 1:15 PM EDTLEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly EarningsLEAP THERAPEUTICS ($LPTX) posted quarterly earnings results on Wednesday, March 26th. The company reported earnings of -$0.37 per share, missing estimates of -$0.37 by $0.00. The company also reported revenue of $0, equaling estimates of $0 by $0.
- RTTNews · Mar 26, 7:42 AM EDTLeap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer(RTTNews) – Leap Therapeutics, Inc. (LPTX) Wednesday reported positive preliminary data from DeFianCe Phase 2 study of sirexatamab, the company's most advanced drug candidate, in colorectal cancer.
- Quiver Quantitative · Mar 15, 5:05 PM EDTLEAP THERAPEUTICS Earnings Preview: Recent $LPTX Insider Trading, Hedge Fund Activity, and MoreLEAP THERAPEUTICS ($LPTX) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.39 per share.
- RTTNews · Jan 28, 8:24 AM ESTLeap Therapeutics Plummets On Disappointing DisTinGuish Study Results In Gastric Cancer(RTTNews) – Shares of Leap Therapeutics Inc. (LPTX) are down over 60% at $0.83 in premarket trading Tuesday, following disappointing results from Part C of its DisTinGuish study.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cypherpunk Technologies Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.